Identification of berberine as a potential therapeutic strategy for kidney clear cell carcinoma and COVID-19 based on analysis of large-scale datasets

Zheng, Zhihua Christoph; Li, Xiushen; Nie, Kechao; Wang, Xiaoyu; Liang, Wencong; Yang, Fan; Zheng, Kairi; Zheng, Yihou

doi:10.3389/fimmu.2023.1038651

Cited by 1 publication

(1 citation statement)

References 82 publications

(86 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of the strong antiviral effects of berberine against a wide range of viruses, some researchers have decided to test this alkaloid against the newly emerging virus SARS-CoV-2. In recent years, several review/research/trial studies have been published on the capabilities of berberine in the fight against SARS-CoV-2 and the treatment of coronavirus disease of 2019 (COVID-19); , here we will have a brief overview of the results of some of the studies. In an in vitro study conducted by Varghese et al, the antiviral activity of berberine against SARS-CoV-2 was assessed using Vero E6 and nasal epithelial cells.…”

Section: Antiviral Activitymentioning

confidence: 99%

Recent Applications of Protoberberines as Privileged Starting Materials for the Development of Novel Broad-Spectrum Antiviral Agents: A Concise Review (2017–2023)

Valipour,

Zakeri Khatir,

Abdollahi

et al. 2023

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

Berberine is a well-known phytochemical with significant antiviral activity against a wide range of viruses. Due to having a unique backbone consisting of four interconnected rings, it can be used as a platform for the design and development of novel semisynthetic antiviral agents. The question here is whether novel broad-spectrum antiviral drugs with enhanced activity and toxicity potential can be obtained by attempting to modify the structure of this privileged lead compound. The present study aims to review the results of recent studies in which berberine and its close analogues (protoberberine alkaloids) have been used as starting materials for the production of new semisynthetic antiviral structures. For this purpose, relevant studies published in high-quality journals indexed in databases such as Scopus, Web of Science, PubMed, etc. in the time frame of 2017 to 2023 were collected. Our selection criterion in the current review focuses on the studies in which protoberberines were used as starting materials for the production of semisynthetic agents with antiviral activity during the indicated time period. Correspondingly, studies were identified in which semisynthetic derivatives with significant inhibitory activity against a wide range of viruses including human immunodeficiency virus (HIV), enterovirus 71 (EV71), zika virus (ZIKV), influenza A/B, cytomegalovirus (CMV), respiratory syncytial virus (RSV), and coxsackieviruses were designed and synthesized. Our conclusion is that, despite the introduction of diverse semisynthetic derivatives of berberine with improved activity profiles compared to the parent natural leads, sufficient derivatization has not been done yet and more studies are needed.

show abstract

Section: Antiviral Activitymentioning

confidence: 99%